- Investors & Media
- Investors & Media
- Contact Us
New results in T1D pediatric patients indicate 60% of patients still maintain active pancreatic beta cells that secrete self-insulin approximately 10 months after last Glassia treatment
Large percentage of patients have very good glycemic control; Phase II/III trial to initiate by end of 2013
European Phase 2/3 trial of inhaled AAT for AATD to complete by year-end
Adjusting 2013 revenue guidance; product sales from Baxter remain on track
Conference call begins today at 8:30 a.m. Eastern time
Kamada management will host an investment community conference call on Tuesday, October 29, 2013 beginning at 8:30 a.m. Eastern time
NESS ZIONA, Israel (September 4, 2013) – Kamada Ltd. (Nasdaq and TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that Gil Efron, Kamada's Chief Financial Officer,…
Net Income of $1 million and Adjusted EBITDA of $4 million; Phase 3 clinical trial of Inhaled AAT for AATD in EU on track to complete this year; Conference Call Begins Today at 10:00 a.m. Eastern Time.
This study examined transplant survival of pancreatic islets originating in other (xeno) species donors. in combination with Glassia, there was a significant time extension in graft acceptance and a higher rate of graft acceptance compared with groups that did not receive Glassia.
the Company was granted two key patents related to its novel Alpha-1 Antitrypsin (AAT) product to treat respiratory diseases.
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced that trading of Kamada Ltd. (Nasdaq:KMDA), a plasma-derived protein therapeutics company, commenced on The NASDAQ Stock Market on Friday, May 31, 2013.
Kamada Ltd. today announced the pricing of its initial public offering in the United States of 5,582,636 ordinary shares at a price to the public of $9.25 per ordinary share.
Total revenue from sales of Glassia in USA is expected to grow: minimum revenues of approximately $165 million